Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV

Overview

cited authors

Sridhar, Vikas S.; Cosentino, Francesco; Dagogo-Jack, Samuel; Mcguire, Darren K.; Pratley, Richard E.; Cater, Nilo B.; Noyes Essex, Margaret; Mancuso, James P.; Zhao, Yujie; Cherney, David Z. I.

authors

Pratley, Richard Edwin, MD

Publication Date

September 2, 2024

webpage

Web of Science

published in

DIABETES OBESITY & METABOLISM Journal

Research

keywords

SGLT2 inhibitor
clinical trial
diabetic nephropathy
inflammation
phase III trial
type 2 diabetes mellitus

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.